Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company based in Bethesda, MD, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' chairman and chief executive officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding chief executive officer and advisor, international business development.

In January 2006, Sucampo received marketing approval from the U.S. Food and Drug Administration for its first product, AMITIZAŽ (lubiprostone) (24 mcg), for the treatment of Chronic Idiopathic Constipation in adults. In April 2008, AMITIZA (8 mcg) was approved by the FDA for a second indication, Irritable Bowel Syndrome with Constipation (IBS-C) in women 18 years and older.

 

Jul 29, 2010
Sucampo to Release Second Quarter 2010 Financial Results and Conduct a Conference Call on August 5, 2010

Jun 8, 2010
Lubiprostone Successfully Completes Phase 3 Efficacy Trial in Japanese Patients Suffering from Chronic Idiopathic Constipation

Jun 4, 2010
R-Tech Ueno Discloses Results of Phase 2 Retinitis Pigmentosa Clinical Trial